JP2008516593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516593A5 JP2008516593A5 JP2007536196A JP2007536196A JP2008516593A5 JP 2008516593 A5 JP2008516593 A5 JP 2008516593A5 JP 2007536196 A JP2007536196 A JP 2007536196A JP 2007536196 A JP2007536196 A JP 2007536196A JP 2008516593 A5 JP2008516593 A5 JP 2008516593A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- group
- polypeptide
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 13
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 13
- 210000002744 extracellular matrix Anatomy 0.000 claims 13
- 238000000034 method Methods 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 230000015556 catabolic process Effects 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 238000006731 degradation reaction Methods 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 108020004459 Small interfering RNA Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 108091081021 Sense strand Proteins 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000003150 biochemical marker Substances 0.000 claims 1
- 230000008236 biological pathway Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61938404P | 2004-10-15 | 2004-10-15 | |
| US60/619,384 | 2004-10-15 | ||
| PCT/EP2005/055315 WO2006040357A2 (en) | 2004-10-15 | 2005-10-17 | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008516593A JP2008516593A (ja) | 2008-05-22 |
| JP2008516593A5 true JP2008516593A5 (cg-RX-API-DMAC7.html) | 2008-12-04 |
| JP4879906B2 JP4879906B2 (ja) | 2012-02-22 |
Family
ID=35840637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536196A Expired - Fee Related JP4879906B2 (ja) | 2004-10-15 | 2005-10-17 | 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7485468B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1817411B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4879906B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE534732T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006040357A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1412371B1 (en) | 2001-07-12 | 2016-02-24 | University of Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| EP2270160A1 (en) * | 2004-06-14 | 2011-01-05 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases |
| DK1948235T3 (da) | 2005-11-01 | 2013-11-25 | Abbvie Biotechnology Ltd | Fremgangsmåder til bestemmelse af effektiviteten af adalimumab hos patienter med Bechterews sygdom med CTX-II og MMP3 som biomarkører |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| JP2010538244A (ja) * | 2007-06-20 | 2010-12-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法 |
| WO2009143372A2 (en) * | 2008-05-21 | 2009-11-26 | Intradigm Corporation | Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof |
| WO2009143603A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| WO2010004051A1 (en) * | 2008-07-11 | 2010-01-14 | Medizinische Universität Innsbruck | Antagonists of nr2f6 for augmenting the immune response |
| EP2322220B1 (en) | 2008-08-01 | 2014-01-01 | Axis, Inc. | Therapeutic agent or preventive agent for osteoarthritis |
| US20150283164A1 (en) * | 2008-11-14 | 2015-10-08 | Christine Victoria Ichim | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 |
| US20150297627A1 (en) * | 2008-11-14 | 2015-10-22 | Christine Victoria Ichim | Methods and Compositions for treatment of cancer by inhibition of NR2F2 |
| US20150203846A1 (en) * | 2008-11-14 | 2015-07-23 | Christine Victoria Ichim | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F6 |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| EP3831954A3 (en) * | 2008-11-17 | 2021-10-13 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| JP2012517821A (ja) * | 2009-02-19 | 2012-08-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物 |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| EP3043179B1 (en) | 2009-04-01 | 2020-05-06 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| CN102459636B (zh) | 2009-05-07 | 2016-08-17 | 威拉赛特公司 | 用于诊断甲状腺病症的方法和组合物 |
| EP2493926B1 (en) * | 2009-10-27 | 2020-03-11 | UCB Biopharma SRL | Function modifying nav 1.7 antibodies |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| US8685931B2 (en) * | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| JPWO2011093083A1 (ja) | 2010-01-29 | 2013-05-30 | Ａｘｉｓ株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
| JP2012246222A (ja) | 2010-01-29 | 2012-12-13 | Axis Inc | 変形性関節症治療剤または予防剤を製造するための使用 |
| WO2011093081A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療剤を含有する注射剤 |
| PT2585596T (pt) | 2010-06-23 | 2021-03-23 | Curna Inc | Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| WO2013166264A2 (en) * | 2012-05-02 | 2013-11-07 | University Of Georgia Research Foundation, Inc. | Methods for altering virus replication |
| AU2013302365B2 (en) | 2012-08-16 | 2019-03-21 | Mayo Foundation For Medical Education And Research | Cancer diagnostics using biomarkers |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| JP2016528236A (ja) * | 2013-08-07 | 2016-09-15 | アスチュート メディカル，インコーポレイテッド | 生物学的試料において改善された性能を有するｔｉｍｐ２のためのアッセイ |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| JP7356788B2 (ja) | 2014-11-05 | 2023-10-05 | ベラサイト インコーポレイテッド | 機械学習および高次元転写データを使用して経気管支生検における特発性肺線維症を診断するシステムおよび方法 |
| WO2017019660A1 (en) * | 2015-07-27 | 2017-02-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
| EP3417063A1 (en) * | 2016-02-15 | 2018-12-26 | Istituti Clinici Scientifici Maugeri SpA SB | Method of allele specific silencing for the treatment of autosomal dominant catecholaminergic polymorphic ventricular tachycardia (cpvt) |
| CN110506127B (zh) | 2016-08-24 | 2024-01-12 | 维拉科特Sd公司 | 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途 |
| CA3050984A1 (en) | 2017-01-20 | 2018-07-26 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
| CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
| CN110996969B (zh) | 2017-07-28 | 2023-02-28 | 杏林制药株式会社 | 纤维化疾病治疗剂 |
| US12497660B2 (en) | 2017-08-04 | 2025-12-16 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| CA3085576A1 (en) | 2017-12-13 | 2019-06-20 | The Research Foundation For The State University Of New York | Peptides and other agents for treating pain and increasing pain sensitivity |
| BR112022024420A2 (pt) | 2020-06-18 | 2023-01-17 | Alnylam Pharmaceuticals Inc | Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas |
| WO2025059345A1 (en) * | 2023-09-14 | 2025-03-20 | Empirico Inc. | Treatment of hgfac related diseases and disorders |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPH0238040B2 (ja) | 1983-06-29 | 1990-08-28 | Matsushita Electric Ind Co Ltd | Sojushinsochi |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU4769893A (en) | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US5459036A (en) | 1993-03-19 | 1995-10-17 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Extracellular signal-regulated kinase, sequences, and methods of production and use |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| DK0789575T3 (da) * | 1994-11-02 | 2009-01-12 | Nps Pharma Inc | Perifer-nerve-system-specifikke natriumkanaler, DNA kodende derfor, screening af lægemidler og fremgangsmåder til fremstilling og anvendelse deraf |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6699983B1 (en) * | 1995-12-21 | 2004-03-02 | Sunnybrook Health Sciences Centre | Integrin-linked kinase and its uses |
| US20090081228A1 (en) * | 1996-03-15 | 2009-03-26 | Munin Corporation | Cyr61 compositions and methods |
| US6162613A (en) | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| WO2000036096A1 (en) | 1998-12-16 | 2000-06-22 | Vertex Pharmaceuticals Incorporated | Crystallized p38 complexes |
| US6753314B1 (en) | 1999-04-01 | 2004-06-22 | Curagen Corporation | Protein-protein complexes and methods of using same |
| AU4031700A (en) | 1999-04-06 | 2000-11-02 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion |
| US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| AU2002213084A1 (en) | 2000-10-11 | 2002-04-22 | Avalon Pharmaceuticals | Cancer-linked genes as targets for chemotherapy |
| EP1412387A2 (en) * | 2000-10-27 | 2004-04-28 | Incyte Genomics, Inc. | Transporters and ion channels |
| AU2002253104A1 (en) | 2001-03-07 | 2002-09-19 | Galapagos Genomics B.V. | Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds |
| WO2002098355A2 (en) * | 2001-06-01 | 2002-12-12 | Clingenix, Inc. | Methods and reagents for diagnosis and treatment of insulin resistance and related conditions |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| WO2003025148A2 (en) * | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US20040072192A1 (en) | 2001-10-11 | 2004-04-15 | Young Paul E | Cancer-linked genes as targets for chemotherapy |
| WO2003083046A2 (en) * | 2002-03-08 | 2003-10-09 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| WO2003076651A2 (en) * | 2002-03-14 | 2003-09-18 | Qlt Inc. | Cancer associated araf1 protein kinase and its uses |
| WO2003081210A2 (en) | 2002-03-21 | 2003-10-02 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
| WO2003085125A1 (en) * | 2002-04-03 | 2003-10-16 | Agy Therapeutics, Inc. | Use of biomolecular targets in the treatment and visualization of brain tumors |
| US20040096836A1 (en) * | 2002-11-19 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of mitogen-activated protein kinase 13 expression |
| US20040110145A1 (en) * | 2002-12-09 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of MALT1 expression |
| US20040197792A1 (en) * | 2002-07-15 | 2004-10-07 | Sugen, Inc. | Novel Kinases |
| WO2004039955A2 (en) * | 2002-10-29 | 2004-05-13 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| CA2506630A1 (en) * | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | Heart failure gene determination and therapeutic screening |
| WO2004058805A2 (en) * | 2002-12-26 | 2004-07-15 | Asahi Kasei Pharma Corporation | T cell activating gene |
| AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| EP2270160A1 (en) * | 2004-06-14 | 2011-01-05 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases |
| EP1759203A2 (en) * | 2004-06-21 | 2007-03-07 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| DE102004049897B4 (de) | 2004-10-13 | 2007-11-22 | Sirs-Lab Gmbh | Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens |
| US20070224662A1 (en) | 2004-12-17 | 2007-09-27 | Jun Luo | Post-translational modification of proteins in cell-free expression systems |
| DE102005013013A1 (de) | 2005-03-21 | 2006-09-28 | Sirs-Lab Gmbh | Verwendung von Genaktivitäts-Klassifikatoren für die in vitro Klassifizierung von Genexpressionsprofilen von Patienten mit infektiösem/nichtinfektiösem Multiorganversagen |
| US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
-
2005
- 2005-10-14 US US11/251,465 patent/US7485468B2/en not_active Expired - Fee Related
- 2005-10-17 JP JP2007536196A patent/JP4879906B2/ja not_active Expired - Fee Related
- 2005-10-17 EP EP05803408A patent/EP1817411B1/en not_active Expired - Lifetime
- 2005-10-17 WO PCT/EP2005/055315 patent/WO2006040357A2/en not_active Ceased
- 2005-10-17 AT AT05803408T patent/ATE534732T1/de active
- 2005-10-17 EP EP11154125.6A patent/EP2360478B1/en not_active Expired - Lifetime
-
2009
- 2009-01-27 US US12/360,332 patent/US8097408B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516593A5 (cg-RX-API-DMAC7.html) | ||
| JP4879906B2 (ja) | 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法 | |
| JP6437467B2 (ja) | 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 | |
| JP2008502355A5 (cg-RX-API-DMAC7.html) | ||
| JP2018513384A (ja) | Ｒｏｒ１−ｒｏｒ２結合のモジュレーター | |
| JP2002521055A (ja) | ９８個のヒト分泌タンパク質 | |
| JP2008503712A5 (cg-RX-API-DMAC7.html) | ||
| JP5128273B2 (ja) | 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ | |
| JP2010538244A (ja) | 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法 | |
| WO2008147938A2 (en) | Wnt5a as an inflammatory disease marker | |
| JP2016522675A (ja) | 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター | |
| US20120004160A1 (en) | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation | |
| WO2005121778B1 (en) | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases | |
| EP2210112B1 (en) | Diagnostic methods for hiv infection | |
| JP2007533989A5 (cg-RX-API-DMAC7.html) | ||
| WO2011140365A1 (en) | Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid | |
| Ishida et al. | Plasma high-mobility group box 1 (HMGB1) in dogs with various diseases: comparison with C-reactive protein | |
| AU2020278977B2 (en) | GPCR heteromer inhibitors and uses thereof | |
| TWI359271B (en) | Pharmaceutical composition for insulin resistance | |
| EP2795337B1 (en) | Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions | |
| JP2016518812A (ja) | 線維症治療において有用な分子標的及び前記標的のインヒビター | |
| WO2001096372A2 (en) | Zinc transporters proteins and their use in medicinal preparations | |
| CN113811321B (zh) | 新型选择性ackr3调节剂及其用途 | |
| US20110293635A1 (en) | Composition and methods for modulating toll-like receptor activity | |
| US20230277618A1 (en) | Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex |